Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Hyo-Soo Kim
- Target Recruit Count
- 304
- Registration Number
- NCT03860220
Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis
- Conditions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- University of Michigan
- Registration Number
- NCT03722381
- Locations
- 🇺🇸
University of Michigan Dialysis, Ann Arbor, Michigan, United States
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 128
- Registration Number
- NCT03666351
- Locations
- 🇰🇷
10 Institutions Including Asan Medical Center, Seoul, Korea, Republic of
Spironolactone Versus Indapamide in Obese and Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT03626506
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Gut Microbiomes in Patients With Metabolic Syndrome
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 1000
- Registration Number
- NCT03489317
- Locations
- 🇭🇰
Lek Yuen Health Centre, Sha Tin, Hong Kong
🇭🇰Department of Microbiology, Chinese University of Hong Kong, Sha Tin, Hong Kong
N-of-1 Trials In Children With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2022-09-09
- Target Recruit Count
- 49
- Registration Number
- NCT03461003
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 233
- Registration Number
- NCT03276598
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- XueQing Yu
- Target Recruit Count
- 11414
- Registration Number
- NCT03264352
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT03226275
- Locations
- 🇨🇳
Xuanwu Hospital, Beijing, China
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hospital General Universitario Gregorio Marañon
- Target Recruit Count
- 106
- Registration Number
- NCT03195023
- Locations
- 🇪🇸
Gregorio Maranon Hospital, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.